Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Budoucí inovace v nové detekci fibrilace síní (FIND-AF): Pilotní studie (FIND-AF)

30. září 2026 aktualizováno: Prof Christopher Gale, University of Leeds

Budoucí inovace v nové detekci fibrilace síní (FIND-AF): Pilotní studie skóre rizika pro včasnou detekci fibrilace síní

The purpose of this study is to trial a new intervention - risk-guided AF screening using an EHR-based risk score and remote ECG monitoring process - and to characterise individuals at elevated predicted AF risk.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Detailní popis

This pilot study will use a post-market device within its intended purpose and involve a change in standard care - that is the offer of ECG monitoring for individuals at risk of AF to understand whether this leads to an increase in detection rates of AF, and follow-through prescription of oral anticoagulation.

Starting with the population that are eligible for oral anticoagulation (men with a CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3), but without AF, this pilot study will use FIND-AF within its intended purpose to predict the absolute risk of AF diagnosis for individuals within the next 6 months. It will be observed whether systematic AF screening leads to higher detection rates of AF in individuals at higher risk for AF than individuals at lower risk for AF.

This will give pilot data for whether systematic screening for AF in individuals at higher AF risk results in an incrementally higher yield of AF detection compared with screening approaches that have been targeted by age and risk of AF-related stroke. If the pilot shows that detection rates for AF are higher in the group at higher AF risk, then it would be suitable to plan a randomised controlled trial to determine whether systematic AF screening guided by AF risk increases detection rates of AF compared with routine care, and whether this is associated with a lower rate of stroke. The detection rates during systematic AF screening in this pilot study for individuals at higher and lower risk can establish power calculations required for a full-scale study and whether the numeric score at which a clinician would implement the intervention can be optimised.

In addition, this pilot study will establish the technical, logistic and administrative feasibility of a full-scale remote AF screening study including issues of recruitment and protocol adherence. It will also inform as to whether individuals diagnosed with AF by systematic AF screening in the community will receive oral anticoagulation interventions in primary care, and thus whether treatment of screen-detected AF in a full-scale study should be implemented in primary care or in secondary care under cardiology.

Finally this study will offer participants at higher AF risk the opportunity to attend a research clinic to determine whether these individuals have risk factors and comorbidities that could be identified and treated to reduce their subsequent risk of AF and other adverse events. This will establish whether individuals at risk of AF will attend for review, and their burden of modifiable risk factors for AF. This will establish power calculations that would be required for a full-scale study to test the hypothesis that primary prevention of AF is possible through interventions aimed at individuals at risk of AF.

Typ studie

Pozorovací

Zápis (Odhadovaný)

1955

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • West Yorkshire
      • Leeds, West Yorkshire, Spojené království, LS2 9JT
        • University of Leeds

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

30 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Patients aged >30 will be invited to screening in primary care from information present in their electronic health record (EHR) and their FIND-AF score. They will be given Zenicor ECG devices for up to period of 3 week during which they will be asked to record 4 daily ECG recordings.

Those patients who are higher risk for AF based on their FIND-AF score, will be reviewed further for multi-modal phenotyping.

Patient with new AF detected will be managed by their primary care clinicians.

Popis

Inclusion Criteria:

  • Age at enrolment ≥30 years
  • Men with CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3

Exclusion Criteria:

  • Known diagnosis of AF
  • On anticoagulation therapy
  • On the palliative care register
  • Unable to give written informed consent for participation in the study
  • Unable to adhere to the study requirements

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Časové okno: 6 months

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

6 months
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Časové okno: 5 years

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

5 years
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Časové okno: 10 years

Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk

10 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Časové okno: 6 months

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

6 months
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Časové okno: 5 years

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

5 years
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Časové okno: 10 years

Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed

10 years

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
To determine the AF detection rates amongst participants who are identified as higher risk and lower risk, including in the periods outside of ECG monitoring to determine the incremental yield that is achieved by ECG monitoring over routine care
Časové okno: 6 months

Risk of recorded AF diagnosis in EHR between individuals identified at higher and lower risk at six months after enrolment

6 months
To determine how diagnostic yield, C statistic/AUROC, NPV, PPV, sensitivity and specificity, varies at different cut off points of the FIND-AF risk score
Časové okno: 6 months

Diagnostic yield, PPV, NPV, sensitivity and specificity amongst participants who receive ECG monitoring, to understand whether the numeric score at which a clinician implements ECG monitoring can be optimised

6 months
To determine the C statistic/AUROC, NPV, PPV, sensitivity and specificity for alternative approaches to guide systematic AF screening in participants who receive ECG monitoring:
Časové okno: 6 months

Diagnostic yield, C statistic/AUROC, PPV, NPV, sensitivity and specificity in patients who are : CHA2DS2VASC≥3 in men and CHA2DS2VASC≥4 in women, age ≥70 years and age 75 and 76 years

6 months
To determine if yield from ECG monitoring varies across age groups (≥75 years and ≤75 years) and sex (men and women)
Časové okno: 6 months

AF detection rates and risks comparing higher and lower risk participants stratified by subgroup

6 months
To determine recruitment rates, overall study.
Časové okno: Up to 24 months

Number (%) of people who consent to participate compared to number of people who are invited

Up to 24 months
To determine withdrawal rates
Časové okno: Up to 24 months

Number (%) of people who consent to participate but subsequently withdraw consent / decline ECG monitoring

Up to 24 months
To determine if there are differences between those who participate and those that do not participate
Časové okno: Up to 24 months

Characteristics of those who consent to participate and do not consent to participate

Up to 24 months
To determine if there are differences between those who participate and those that withdraw
Časové okno: Up to 24 months

Characteristics of those who participate and those that withdraw

Up to 24 months
To determine the adherence of ECG recordings amongst participants
Časové okno: Up to 24 months

Mean number of recordings compared to the maximum stipulated Number (%) of participants who record less than 50% of stipulated amount of ECG recordings

Up to 24 months
To determine the number of ECG recordings that need to be reviewed for possible AF detection
Časové okno: Up to 24 months

Number (%) of ECG recordings flagged as abnormal by the algorithm within ECG recorder software that require manual review to assess for potential AF diagnosis

Up to 24 months
To determine the burden of other arrhythmias that are diagnosed through ECG monitoring in participants identified as higher risk and lower risk
Časové okno: Up to 24 months

Number (%) of participants who are diagnosed with other arrhythmias ( (atrial tachycardia, supraventricular tachycardia, 2nd degree AV block, high grade AV block or 3rd degree heart block, pause/asystole, ventricular tachycardia, ventricular fibrillation) during ECG monitoring in participants

Up to 24 months
To determine the burden of non-diagnostic rhythm reports from ECG monitoring
Časové okno: Up to 24 months

Number (%) of participants who have an ECG monitoring period with consistent poor quality which precludes a diagnostic result

Up to 24 months
To determine recruitment rates - research clinic appointment
Časové okno: Up to 24 months

Number (%) of people who consent to attend a research clinic appointment compared to number of people who are invited

Up to 24 months
To determine what other conditions and cardiovascular risk factors are identified amongst participants classified as higher risk for AF at research clinic
Časové okno: End of recruitment

Descriptive statistics of demographics, morbidities, medications, and cardiac ultrasound findings

End of recruitment
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Časové okno: 5 years from completion of recruitment

Number (%) of participants who experience at 5 years:

  • AF
  • Ischaemic stroke
  • Haemorrhagic stroke
  • Systemic embolism
  • Gastrointestinal or intracranial bleeding
  • Death
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Heart failure
  • Diabetes mellitus
  • Myocardial infarction
  • Peripheral vascular disease
  • Valvular heart disease
5 years from completion of recruitment
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Časové okno: 10 years from completion of recruitment

Number (%) of participants who experience at 10 years:

  • AF
  • Ischaemic stroke
  • Haemorrhagic stroke
  • Systemic embolism
  • Gastrointestinal or intracranial bleeding
  • Death
  • Chronic obstructive pulmonary disease
  • Chronic kidney disease
  • Heart failure
  • Diabetes mellitus
  • Myocardial infarction
  • Peripheral vascular disease
  • Valvular heart disease
10 years from completion of recruitment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Chris Gale, Yes, University of Leeds

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. října 2023

Primární dokončení (Aktuální)

16. června 2025

Dokončení studie (Odhadovaný)

28. února 2033

Termíny zápisu do studia

První předloženo

18. května 2023

První předloženo, které splnilo kritéria kontroly kvality

31. května 2023

První zveřejněno (Aktuální)

12. června 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

2. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 318197_V1.0_230509

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

No individual participant data will be shared.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .